{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:16:41Z","timestamp":1747196201678,"version":"3.40.5"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases, National Institute of Health","award":["R01AI127232"],"award-info":[{"award-number":["R01AI127232"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The risk of HIV pre-exposure prophylaxis (PrEP) failure with sufficient medication adherence is extremely low but has occurred due to transmission of a viral strain with mutations conferring resistance to PrEP components tenofovir (TDF) and emtricitabine (FTC). The extent to which such strains are circulating in the population is unknown.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We used HIV surveillance data to describe primary and overall TDF\/FTC resistance and concurrent viremia among people living with HIV (PLWH). HIV genotypes conducted for clinical purposes are reported as part of HIV surveillance. We examined the prevalence of HIV strains with mutations conferring intermediate to high level resistance to TDF\/FTC, defining primary resistance (predominantly K65R and M184I\/V mutations) among sequences reported within 3 months of HIV diagnosis and total resistance for sequences reported at any time. We examined trends in primary resistance during 2010\u20132019 and total resistance among all PLWH in 2019. We also monitored resistance with viremia (\u22651,000 copies\/mL) at the end of 2019 among PLWH.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Between 2010 and 2019, 2,172 King County residents were diagnosed with HIV; 1,557 (72%) had a genotypic resistance test within three months; three (0.2%) had primary TDF\/FTC resistance with both K65R and M184I\/V mutations. Adding isolated resistance for each drug resulted in 0.3% with primary TDF resistance and 0.8% with primary FTC resistance. Of 7,056 PLWH in 2019, 4,032 (57%) had genotype results, 241 (6%) had TDF\/FTC resistance and 15 (0.4% of those with a genotype result) had viremia and TDF\/FTC resistance.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Primary resistance and viremia combined with TDF\/FTC resistance are uncommon in King County. Monitoring trends in TDF\/FTC resistance coupled with interventions to help ensure PLWH achieve and maintain viral suppression may help ensure that PrEP failure remains rare.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0272958","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T17:26:23Z","timestamp":1661793983000},"page":"e0272958","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["A public health approach to monitoring HIV with resistance to HIV pre-exposure prophylaxis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6877-5713","authenticated-orcid":true,"given":"Susan E.","family":"Buskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Lechtenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis A.","family":"Slaughter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua T.","family":"Herbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-4280","authenticated-orcid":true,"given":"Roxanne P.","family":"Kerani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Golden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia C.","family":"Dombrowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"pone.0272958.ref001","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"New Engl Jour Med"},{"key":"pone.0272958.ref002","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre- exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"PL Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"pone.0272958.ref003","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","article-title":"Single-agent tenofovir versus combination emtricitabine plus tenofovir for preexposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, doubleblind, phase 3 trial","volume":"14","author":"JM Baeten","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"pone.0272958.ref004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"S McCormack","year":"2016","journal-title":"Lancet"},{"key":"pone.0272958.ref005","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV Epidemic: A Plan for the United States","volume":"321","author":"AS Fauci","year":"2019","journal-title":"JAMA"},{"key":"pone.0272958.ref006","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMc1611639","article-title":"Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis","volume":"376","author":"DC Knox","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0272958.ref007","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/QAI.0000000000001534","article-title":"Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis","volume":"76","author":"M Markowitz","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0272958.ref008","first-page":"30288","article-title":"Acquisition of tenofovir-susceptible, emtricitabine- resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report","volume":"S2352-3018","author":"SE Cohen","year":"2018","journal-title":"Lancet HIV"},{"key":"pone.0272958.ref009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hiv.12989","article-title":"A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections","volume":"22","author":"KW To","year":"2021","journal-title":"HIV Med"},{"key":"pone.0272958.ref010","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/09540121.2017.1316356","article-title":"Receipt and timing of HIV drug resistance testing in six U.S. jurisdictions","volume":"29","author":"S Dasgupta","year":"2017","journal-title":"AIDS Care"},{"key":"pone.0272958.ref011","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annepidem.2017.02.002","article-title":"Increasing HIV-1 subtype diversity in seven states, United States, 2006\u20132013","volume":"27","author":"AM Oster","year":"2017","journal-title":"Ann Epidemiol"},{"key":"pone.0272958.ref012","first-page":"515","article-title":"Dramatic increase in preexposure prophylaxis use among MSM in Washington state","volume":"30","author":"JE Hood","year":"2016","journal-title":"AIDS"},{"key":"pone.0272958.ref013","unstructured":"Khosropour C, Hood J, Rao D, Spellman D, Katz D, Thibault T, et al. Pre-Exposure Prophylaxis (PrEP) in King County, Washington. HIV\/AIDS Epidemiology Unit, Public Health\u2013Seattle & King County and the Infectious Disease Assessment Unit, Washington State Department of Health. HIV\/AIDS Epidemiology Unit, Public Health\u2013Seattle & King County and the Infectious Disease Assessment Unit, Washington State Department of Health. HIV\/ AIDS Epidemiology Report 2017, Volume 86. https:\/\/kingcounty.gov\/depts\/health\/communicable-diseases\/hiv-std\/patients\/epidemiology\/~\/media\/depts\/health\/communicable- diseases\/documents\/hivstd\/2017-hiv-aids-epidemiology-annual-report.ashx. Accessed 6\/28\/2021."},{"key":"pone.0272958.ref014","unstructured":"HIV\/AIDS Epidemiology Unit, Public Health\u2013Seattle & King County and the Infectious Disease Assessment Unit, Washington State Department of Health. HIV\/AIDS Epidemiology Report 2019, Volume 88. https:\/\/www.kingcounty.gov\/depts\/health\/communicable-diseases\/hiv-std\/patients\/~\/media\/depts\/health\/communicable-diseases\/documents\/hivstd\/2019-hiv-aids-epidemiology-annual-report.ashx. Accessed 3\/17\/2021."},{"key":"pone.0272958.ref015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.annepidem.2020.01.004","article-title":"Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions","volume":"44","author":"PS Sullivan","year":"2020","journal-title":"Ann Epidemiol"},{"key":"pone.0272958.ref016","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2105\/AJPH.2017.304069","article-title":"Integrating HIV Surveillance and Field Services: Data Quality and Care Continuum in King County, Washington, 2010\u20132015","volume":"107","author":"JE Hood","year":"2017","journal-title":"Am J Public Health"},{"key":"pone.0272958.ref017","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"TF Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"pone.0272958.ref018","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1089\/apc.2013.0302","article-title":"Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges","volume":"28","author":"JM McMahon","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"pone.0272958.ref019","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM200003303421303","article-title":"Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group","volume":"342","author":"TC Quinn","year":"2000","journal-title":"N Engl J Med"},{"key":"pone.0272958.ref020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/QAD.0000000000002394","article-title":"HIV drug resistance in a cohort of HIV- infected MSM in the United States","volume":"34","author":"JM Fogel","year":"2020","journal-title":"AIDS"},{"key":"pone.0272958.ref021","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3851\/IMP3302","article-title":"Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP","volume":"24","author":"J Younger","year":"2019","journal-title":"Antivir Ther"},{"key":"pone.0272958.ref022","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/QAD.0000000000000640","article-title":"Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care","volume":"29","author":"G Marks","year":"2015","journal-title":"AIDS"},{"key":"pone.0272958.ref023","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1097\/QAD.0000000000001960","article-title":"Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial","volume":"32","author":"C Delaugerre","year":"2018","journal-title":"AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T17:26:54Z","timestamp":1661794014000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272958"}},"subtitle":[],"editor":[{"given":"Ngai Sze","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0272958","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,8,29]]}}}